To the Editor: Patients with lung cancer who respond to gefitinibhave been reported to have somatic mutations consisting of deletionsin exon 19 and the L858R mutation in exon 21 of the epidermalgrowth factor receptor (EGFR) gene.1 In addition, a second mutation(T790M) in exon 20 is also associated with acquired resistanceto gefitinib in initially gefitinib-sensitive patients.2,3 Wedescribe a patient with gefitinib-resistant lung adenocarcinomaharboring both T790M and L858R at diagnosis.
A 55-year-old woman who had never smoked presented with blurredvision and slurred speech. Magnetic resonance imaging of thebrain disclosed a rim-enhanced . . . [Full Text of this Article]
This article has been cited by other articles:
Wu, S.-G., Chang, Y.-L., Hsu, Y.-C., Wu, J.-Y., Yang, C.-H., Yu, C.-J., Tsai, M.-F., Shih, J.-Y., Yang, P.-C.
(2008). Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR) Mutations with the Classical Mutation Pattern. The Oncologist
13: 1276-1284
[Abstract][Full Text]
Stinchcombe, T. E., Socinski, M. A.
(2008). Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?. The Oncologist
13: 933-944
[Abstract][Full Text]
Wu, J.-Y., Wu, S.-G., Yang, C.-H., Gow, C.-H., Chang, Y.-L., Yu, C.-J., Shih, J.-Y., Yang, P.-C.
(2008). Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response. Clin. Cancer Res.
14: 4877-4882
[Abstract][Full Text]
Sequist, L. V., Joshi, V. A., Janne, P. A., Muzikansky, A., Fidias, P., Meyerson, M., Haber, D. A., Kucherlapati, R., Johnson, B. E., Lynch, T. J.
(2007). Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.. The Oncologist
12: 90-98
[Abstract][Full Text]
Giaccone, G., Gallegos Ruiz, M., Le Chevalier, T., Thatcher, N., Smit, E., Rodriguez, J. A., Janne, P., Oulid-Aissa, D., Soria, J.-C.
(2006). Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study.. Clin. Cancer Res.
12: 6049-6055
[Abstract][Full Text]
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., Mitsudomi, T.
(2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.. Clin. Cancer Res.
12: 5764-5769
[Abstract][Full Text]
Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., Suehisa, H., Ouchida, M., Aoe, K., Aoe, M., Kiura, K., Shimizu, N., Date, H.
(2006). Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Non-Small Cell Lung Cancer. Cancer Res.
66: 7854-7858
[Abstract][Full Text]
von Bubnoff, N., Manley, P. W., Mestan, J., Sanger, J., Peschel, C., Duyster, J.
(2006). Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood
108: 1328-1333
[Abstract][Full Text]
Van Schaeybroeck, S., Kyula, J., Kelly, D. M., Karaiskou-McCaul, A., Stokesberry, S. A., Van Cutsem, E., Longley, D. B., Johnston, P. G.
(2006). Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Molecular Cancer Therapeutics
5: 1154-1165
[Abstract][Full Text]